Agonists of PPARγ, such as thiazolidinediones (e.g., pioglitazone, rosiglitazone), enhance insulin sensitivity and regulate glucose metabolism, making them effective treatments for type 2 diabetes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.